Response: [adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial]

Irwin Gross and Michael Auerbach address questions related to oral vs intravenous iron substitution in cancer patients receiving erythropoiesis stimulating agen

Saved in:
Bibliographic Details
Main Authors: Möbus, Volker (Author) , Jackisch, Christian (Author) , Schneeweiss, Andreas (Author) , Huober, Jens (Author) , Lück, Hans-Joachim (Author) , Du Bois, Andreas (Author) , Thomssen, Christoph (Author) , Kurbacher, Christian M. (Author) , Kuhn, Walther (Author) , Nitz, Ulrike A. (Author) , Runnebaum, Ingo B. (Author) , Hinke, Axel (Author) , Kreienberg, Rolf (Author) , Untch, Michael (Author)
Format: Article (Journal) Editorial
Language:English
Published: 28 February 2014
In: Journal of the National Cancer Institute
Year: 2014, Volume: 106, Issue: 3, Pages: 452
ISSN:1460-2105
DOI:10.1093/jnci/djt452
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/jnci/djt452
Verlag, Volltext: http://www.ncbi.nlm.nih.gov/pubmed?term=24586093
Verlag, lizenzpflichtig, Volltext: https://academic.oup.com/jnci/article/106/3/djt452/977620
Get full text
Author Notes:Volker Moebus, Christian Jackisch, Andreas Schneeweiss, Jens Huober, Hans-Joachim Lueck, Andreas du Bois, Christoph Thomssen, Christian Kurbacher, Walther Kuhn, Ulrike A. Nitz, Ingo B. Runnebaum, Axel Hinke, Rolf Kreienberg, Michael Untch, AGO Breast Study Group
Description
Summary:Irwin Gross and Michael Auerbach address questions related to oral vs intravenous iron substitution in cancer patients receiving erythropoiesis stimulating agen
Physical Description:Online Resource
ISSN:1460-2105
DOI:10.1093/jnci/djt452